Streetbeat News

Products Services

NTRB

NTRBW

Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) has increased its existing credit line to $5 million to support the continued development and regulatory submission process for its patented lead product platform, AVERSA™ Fentanyl. The company is targeting FDA submission for AVERSA™ Fentanyl in the first half of 2024. AVERSA™ Fentanyl, which combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva Drug Delivery’s FDA-approved transdermal fentanyl patch system, is estimated to reach peak annual US sales of $80M - $200M.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:21 pm

CJET

Chijet Motor Company, Inc. (NASDAQ:CJET) announced that its majority-owned subsidiary FAW Jilin Automobile Co., Ltd. has completed its first shipment of automobile orders to Peru through its newly developed export operation at Tianjin Port, China. This marks the official opening of FAW Jilin's dual-channel export model, indicating a new phase of development for the company's international marketing business.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:20 pm

THRX

Theseus Pharmaceuticals Inc (NASDAQ:THRX) has decided to terminate the development of THE-630 for gastrointestinal stromal tumors (GIST) due to dose-limiting toxicities. The company will discontinue enrollment in the ongoing phase 1/2 study. The decision was made after observing hand-foot skin reactions in patients. The company is now prioritizing THE-349 for EGFR mutant non-small cell lung cancer and announced a new program targeting KIT for patients with early-line GIST. Following the news, THRX shares are down 65.50%.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 1:19 pm

CVM

CEL-SCI Corporation (NYSE:CVM) has concluded a meeting with the U.S. FDA regarding the approval of Multikine for the treatment of head and neck cancer. The FDA acknowledged the need for improved treatments and is open to collaboration with CEL-SCI. The company is also pursuing approval in Europe, the UK, and Canada, with commercialization possibly beginning in 2024 if Health Canada approves the submission. CEL-SCI's CEO highlighted the drug's potential benefits, including a 4-year median survival benefit and complete tumor elimination in some patients within 3 weeks.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:15 pm

LAES

WKEY

WISeKey International Holding Ltd. (NASDAQ:WKEY) and its subsidiaries, SEALSQ Corp (NASDAQ:LAES) and WISeSat AG, are developing an ultra-secure picosatellite solution for Quantum-Ready IoT communications. The new generation of WISeSat-ready satellites will incorporate post-quantum solutions, with microchips and devices designed to withstand the evolution of computational power. Seventeen WISeSat-ready satellites have already been launched into orbit with SpaceX as part of an 80-satellite constellation.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:13 pm

META

TSLA

The rivalry between Tesla CEO Elon Musk and Meta Platforms CEO Mark Zuckerberg is intensifying, with both billionaires competing in terms of employee salaries and social media platforms. Musk's Twitter and Zuckerberg's Threads are in direct competition, with Musk threatening a lawsuit over alleged intellectual property theft. Average annual pay at Tesla ranges from $50,000 to $260,000, while at Meta, salaries range from $100,000 to over $400,000. Musk also offered stock grants to Twitter employees at a $20 billion valuation.

Portfolio Pulse from Adam Eckert

July 14, 2023 | 1:10 pm

BANL

Banle Energy International Limited, a subsidiary of CBL International Limited (NASDAQ:BANL), has launched its first B24 biofuel bunkering operation in Hong Kong in partnership with ASB Biodiesel and Seven Seas Oil. The move is part of the company's efforts to support the 2023 IMO Greenhouse Gas Strategy, which aims to reduce greenhouse gas emissions from international shipping. The company's CEO, Teck Lim Chia, stated that the operation is a significant step towards environmental sustainability and reducing carbon emissions in the shipping industry.

Portfolio Pulse from Benzinga Newsdesk

July 14, 2023 | 12:47 pm

ACAD

JPM

ROIV

Roivant Sciences is in talks with Roche for a $7 billion stomach disease drug deal. JPMorgan's Q2 investment banking revenue is up 11% to $1.5B, but total markets revenue is down 10% to $7B. Acadia Pharmaceuticals acquires ex-North American rights to Trofinetide and global rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X Syndrome for an upfront payment of $100M.

Portfolio Pulse from Benzinga Newsdesk

July 14, 2023 | 12:35 pm

DBX

HOOD

PINS

SNX

Insiders at Pinterest (PINS), Dropbox (DBX), Robinhood Markets (HOOD), and TD SYNNEX (SNX) have recently sold significant amounts of shares. While insider sales can sometimes indicate concern about a company's prospects, they can also be part of a preplanned sale. Recent developments for these companies include a stock upgrade for Pinterest by Wells Fargo, the announcement of new AI-powered products by Dropbox, multiple firms raising their price targets for Robinhood, and TD SYNNEX reporting worse-than-expected Q2 financial results.

Portfolio Pulse from Lisa Levin

July 14, 2023 | 12:22 pm

ACAD

ACADIA Pharmaceuticals has acquired ex-North American rights to trofinetide and global rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X syndrome. The company also announced guidance.

Portfolio Pulse from Benzinga Newsdesk

July 14, 2023 | 12:10 pm